NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Dec 2015
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
BRIDION (sugammadex) by Merck & Co. is cyclodextrin. First approved in 2015.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRIDION (sugammadex) is a cyclodextrin-based reversal agent that rapidly restores neuromuscular function by encapsulating rocuronium and vecuronium, the most commonly used neuromuscular blocking agents in anesthesia. It is administered intravenously in operating rooms to reverse neuromuscular blockade at the end of surgery. This mechanism allows anesthesiologists to regain patient control and reduce post-operative complications.
LOE Approaching1.1 years to LOE
Product is within 1.2 years of loss of exclusivity, signaling transition planning and potential downsizing of brand teams; mid-sized promotional footprint expected in final years.
Mechanism of Action
cyclodextrin. It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
The Effect of Methylprednisolone on the Reversal Time of Rocuronium by Sugammadex in the Pediatric Patient Group
Started Oct 2024
Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
Started Jun 2024
80 enrolled
Neuromuscular Blocks
Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery
Started Aug 2023
118 enrolled
Spine SurgeryReversal of Neuromuscular BlockadeUrinary Retention Postoperative
Sugammadex as Rescue Therapy
Started Jul 2023
46 enrolled
Neuromuscular Blockade
Influence of Neostigmine vs. Sugammadex on PORC and PPCs by Ultrasonography
Started Aug 2021
414 enrolled
Postoperative Pulmonary Complications
Worked on BRIDION at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.